speb/financial-data huggingface dataset:
GENI income_statement (annual, 2024-12-31) — Gain On Sale Of Ppe: -147000.00
GENI income_statement (annual, 2024-12-31) — Gain On Sale Of Security: -9519000.00
GENI balance_sheet (annual, 2024-12-31) — Gains Losses Not Affecting Retained Earnings: -24635000.00
GENI income_statement (annual, 2024-12-31) — General And Administrative Expense: 123011000.00
GENI balance_sheet (annual, 2024-12-31) — Goodwill: 326011000.00
GENI balance_sheet (annual, 2024-12-31) — Goodwill And Other Intangible Assets: 441550000.00
GENI balance_sheet (annual, 2024-12-31) — Gross Accounts Receivable: 90465000.00
GENI balance_sheet (annual, 2024-12-31) — Gross PPE: 46520000.00
GENI income_statement (annual, 2024-12-31) — Gross Profit: 128707000.00
GENI cash_flow (annual, 2024-12-31) — Income Tax Paid Supplemental Data: 2478000.00
GENI balance_sheet (annual, 2024-12-31) — Income Tax Payable: 1295000.00
GENI cash_flow (annual, 2024-12-31) — Interest Paid Supplemental Data: 1224000.00
GENI balance_sheet (annual, 2024-12-31) — Inventory: 482000.00
GENI balance_sheet (annual, 2024-12-31) — Invested Capital: 572424000.00
GENI cash_flow (annual, 2024-12-31) — Investing Cash Flow: -62685000.00
GENI balance_sheet (annual, 2024-12-31) — Investments And Advances: 31717000.00
GENI cash_flow (annual, 2024-12-31) — Issuance Of Capital Stock: 0.00
GENI balance_sheet (annual, 2024-12-31) — Line Of Credit: 19000.00
GENI balance_sheet (quarterly, 2024-12-31) — Line Of Credit: 19000.00
GENI balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 4489000.00
GENI balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 4489000.00
GENI cash_flow (annual, 2024-12-31) — Long Term Debt Payments: -22000.00
GENI cash_flow (quarterly, 2024-12-31) — Long Term Debt Payments: 7569000.00
GENI balance_sheet (annual, 2024-12-31) — Long Term Equity Investment: 31717000.00
GENI balance_sheet (quarterly, 2024-12-31) — Long Term Equity Investment: 31717000.00
GENI balance_sheet (annual, 2024-12-31) — Machinery Furniture Equipment: 20201000.00
GENI balance_sheet (quarterly, 2024-12-31) — Machinery Furniture Equipment: 20201000.00
GENI cash_flow (annual, 2024-12-31) — Net Business Purchase And Sale: 0.00
GENI cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: 0.00
GENI cash_flow (annual, 2024-12-31) — Net Foreign Currency Exchange Gain Loss: 9238000.00
GENI income_statement (annual, 2024-12-31) — Net Income: -63040000.00
GENI income_statement (annual, 2024-12-31) — Net Income Common Stockholders: -63040000.00
GENI income_statement (annual, 2024-12-31) — Net Income Continuous Operations: -63040000.00
GENI income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -63040000.00
GENI income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -63040000.00
GENI cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: -63040000.00
GENI income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: -63040000.00
GENI cash_flow (annual, 2024-12-31) — Net Intangibles Purchase And Sale: 0.00
GENI income_statement (annual, 2024-12-31) — Net Interest Income: 921000.00
GENI cash_flow (annual, 2024-12-31) — Net Investment Purchase And Sale: 0.00
GENI cash_flow (annual, 2024-12-31) — Net Issuance Payments Of Debt: -7597000.00
GENI cash_flow (annual, 2024-12-31) — Net Long Term Debt Issuance: -22000.00
GENI cash_flow (quarterly, 2024-12-31) — Net Long Term Debt Issuance: 7569000.00
GENI income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: 921000.00
GENI cash_flow (annual, 2024-12-31) — Net Other Investing Changes: 10000.00
GENI cash_flow (quarterly, 2024-12-31) — Net Other Investing Changes: 0.00
GENI balance_sheet (annual, 2024-12-31) — Net PPE: 26504000.00
GENI cash_flow (annual, 2024-12-31) — Net PPE Purchase And Sale: -12293000.00
GENI cash_flow (annual, 2024-12-31) — Net Short Term Debt Issuance: -7575000.00
GENI balance_sheet (annual, 2024-12-31) — Net Tangible Assets: 130855000.00
GENI balance_sheet (annual, 2024-12-31) — Non Current Accounts Receivable: 572000.00
GENI balance_sheet (annual, 2024-12-31) — Non Current Deferred Assets: 2339000.00
GENI balance_sheet (annual, 2024-12-31) — Non Current Deferred Liabilities: 13802000.00
GENI balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Assets: 1192000.00
GENI balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Liabilities: 13802000.00
GENI balance_sheet (annual, 2024-12-31) — Non Current Prepaid Assets: 987000.00
GENI income_statement (annual, 2024-12-31) — Normalized EBITDA: 27169000.00
GENI income_statement (annual, 2024-12-31) — Normalized Income: -54438480.00
GENI cash_flow (annual, 2024-12-31) — Operating Cash Flow: 81861000.00
GENI cash_flow (annual, 2024-12-31) — Operating Gains Losses: 5658000.00
GENI income_statement (annual, 2024-12-31) — Operating Income: -56291000.00
GENI income_statement (annual, 2024-12-31) — Operating Revenue: 510894000.00
GENI balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 211156026.00
GENI balance_sheet (annual, 2024-12-31) — Other Current Borrowings: 19000.00
GENI balance_sheet (quarterly, 2024-12-31) — Other Current Borrowings: 19000.00
GENI balance_sheet (annual, 2024-12-31) — Other Current Liabilities: 413000.00
GENI balance_sheet (quarterly, 2024-12-31) — Other Current Liabilities: 413000.00
GENI balance_sheet (annual, 2024-12-31) — Other Equity Adjustments: -24635000.00
GENI income_statement (annual, 2024-12-31) — Other Gand A: 123011000.00
GENI income_statement (annual, 2024-12-31) — Other Income Expense: -10888000.00
GENI balance_sheet (annual, 2024-12-31) — Other Intangible Assets: 115539000.00
GENI cash_flow (annual, 2024-12-31) — Other Non Cash Items: 2577000.00
GENI balance_sheet (annual, 2024-12-31) — Other Payable: 861000.00
GENI balance_sheet (annual, 2024-12-31) — Other Properties: 24418000.00
GENI balance_sheet (annual, 2024-12-31) — Other Receivables: 30683000.00
GENI balance_sheet (annual, 2024-12-31) — Payables: 39544000.00
GENI balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 118716000.00
GENI balance_sheet (annual, 2024-12-31) — Prepaid Assets: 27333000.00
GENI income_statement (annual, 2024-12-31) — Pretax Income: -66258000.00
GENI cash_flow (annual, 2024-12-31) — Proceeds From Stock Option Exercised: 0.00
GENI cash_flow (quarterly, 2024-12-31) — Proceeds From Stock Option Exercised: 0.00
GENI balance_sheet (annual, 2024-12-31) — Properties: 0.00
GENI balance_sheet (quarterly, 2024-12-31) — Properties: 0.00
GENI cash_flow (annual, 2024-12-31) — Provisionand Write Offof Assets: 1630000.00
GENI cash_flow (annual, 2024-12-31) — Purchase Of Business: 0.00
GENI cash_flow (annual, 2024-12-31) — Purchase Of Intangibles: 0.00
GENI cash_flow (annual, 2024-12-31) — Purchase Of Investment: 0.00
GENI cash_flow (annual, 2024-12-31) — Purchase Of PPE: -12293000.00
GENI balance_sheet (annual, 2024-12-31) — Receivables: 124439000.00
GENI income_statement (annual, 2024-12-31) — Reconciled Cost Of Revenue: 382187000.00
GENI income_statement (annual, 2024-12-31) — Reconciled Depreciation: 72572000.00
GENI cash_flow (annual, 2024-12-31) — Repayment Of Debt: -7597000.00
GENI income_statement (annual, 2024-12-31) — Research And Development: 24576000.00
GENI balance_sheet (annual, 2024-12-31) — Restricted Cash: 25026000.00
GENI balance_sheet (quarterly, 2024-12-31) — Restricted Cash: 25026000.00
GENI income_statement (annual, 2024-12-31) — Restructuring And Mergern Acquisition: 1222000.00
GENI balance_sheet (annual, 2024-12-31) — Retained Earnings: -1087527000.00
GENI income_statement (annual, 2024-12-31) — Selling And Marketing Expense: 37411000.00
GENI income_statement (annual, 2024-12-31) — Selling General And Administration: 160422000.00
GENI balance_sheet (annual, 2024-12-31) — Share Issued: 215261974.00
GENI cash_flow (annual, 2024-12-31) — Short Term Debt Payments: -7575000.00
GENI income_statement (annual, 2024-12-31) — Special Income Charges: -1369000.00
GENI cash_flow (annual, 2024-12-31) — Stock Based Compensation: 54475000.00
GENI balance_sheet (annual, 2024-12-31) — Stockholders Equity: 572405000.00
GENI balance_sheet (annual, 2024-12-31) — Tangible Book Value: 130855000.00
GENI income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: -2286480.00
GENI income_statement (annual, 2024-12-31) — Tax Provision: 509000.00
GENI income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.21
GENI balance_sheet (annual, 2024-12-31) — Taxes Receivable: 8265000.00
GENI balance_sheet (annual, 2024-12-31) — Total Assets: 792266000.00
GENI balance_sheet (annual, 2024-12-31) — Total Capitalization: 572405000.00
GENI balance_sheet (annual, 2024-12-31) — Total Debt: 7511000.00
GENI balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 572405000.00
GENI income_statement (annual, 2024-12-31) — Total Expenses: 567185000.00
GENI balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 219861000.00
GENI balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 503669000.00
GENI balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 18291000.00
GENI income_statement (annual, 2024-12-31) — Total Operating Income As Reported: -58537000.00
GENI income_statement (annual, 2024-12-31) — Total Other Finance Cost: -921000.00
GENI income_statement (quarterly, 2024-12-31) — Total Other Finance Cost: 80000.00
GENI balance_sheet (annual, 2024-12-31) — Total Tax Payable: 2022000.00
GENI income_statement (annual, 2024-12-31) — Total Unusual Items: -10888000.00
GENI income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: -10888000.00
GENI balance_sheet (annual, 2024-12-31) — Tradeand Other Payables Non Current: 0.00
GENI balance_sheet (quarterly, 2024-12-31) — Tradeand Other Payables Non Current: 0.00
GENI balance_sheet (annual, 2024-12-31) — Treasury Shares Number: 4105948.00
GENI balance_sheet (annual, 2024-12-31) — Treasury Stock: 17653000.00
GENI balance_sheet (annual, 2024-12-31) — Working Capital: 87027000.00
GENI income_statement (quarterly, 2025-03-31) — +Operating Expense: 54894000.00
GENI income_statement (quarterly, 2025-03-31) — +Total Revenue: 143991000.00
GENI balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 39962000.00
GENI balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 81594000.00
GENI balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 1856644000.00
GENI balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -86000000.00
GENI cash_flow (quarterly, 2025-03-31) — Asset Impairment Charge: 0.00
GENI income_statement (quarterly, 2025-03-31) — Basic Average Shares: 248432320.00
GENI income_statement (quarterly, 2025-03-31) — Basic EPS: -0.03
GENI cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 135239000.00
GENI cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -17473000.00
GENI cash_flow (quarterly, 2025-03-31) — Capital Expenditure Reported: -13349000.00
GENI balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 14408000.00
GENI balance_sheet (quarterly, 2025-03-31) — Capital Stock: 2411000.00
GENI balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 209823000.00
GENI balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 209823000.00
GENI cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: 143995000.00
GENI cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: -14975000.00
GENI cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: -30798000.00
GENI cash_flow (quarterly, 2025-03-31) — Change In Account Payable: 3302000.00
GENI cash_flow (quarterly, 2025-03-31) — Change In Accrued Expense: -12361000.00
GENI cash_flow (quarterly, 2025-03-31) — Change In Other Current Assets: -1680000.00
GENI cash_flow (quarterly, 2025-03-31) — Change In Other Current Liabilities: -7346000.00
GENI cash_flow (quarterly, 2025-03-31) — Change In Other Working Capital: -15193000.00
GENI cash_flow (quarterly, 2025-03-31) — Change In Payable: 3302000.00
GENI cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: -9059000.00
GENI cash_flow (quarterly, 2025-03-31) — Change In Prepaid Assets: -9998000.00
GENI cash_flow (quarterly, 2025-03-31) — Change In Receivables: 2787000.00
GENI cash_flow (quarterly, 2025-03-31) — Change In Working Capital: -40489000.00
GENI cash_flow (quarterly, 2025-03-31) — Changes In Account Receivables: 3802000.00
GENI cash_flow (quarterly, 2025-03-31) — Changes In Cash: 98222000.00
GENI balance_sheet (quarterly, 2025-03-31) — Common Stock: 2411000.00
GENI balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 710843000.00
GENI cash_flow (quarterly, 2025-03-31) — Common Stock Issuance: 144000000.00
GENI income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 108789000.00
GENI balance_sheet (quarterly, 2025-03-31) — Current Accrued Expenses: 66811000.00
GENI balance_sheet (quarterly, 2025-03-31) — Current Assets: 396594000.00
GENI balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 2964000.00
GENI balance_sheet (quarterly, 2025-03-31) — Current Debt: 15000.00
GENI balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 2979000.00
GENI balance_sheet (quarterly, 2025-03-31) — Current Deferred Assets: 1216000.00
GENI balance_sheet (quarterly, 2025-03-31) — Current Deferred Liabilities: 58207000.00
GENI balance_sheet (quarterly, 2025-03-31) — Current Deferred Revenue: 58195000.00
GENI balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 170721000.00
GENI cash_flow (quarterly, 2025-03-31) — Deferred Income Tax: -174000.00
GENI cash_flow (quarterly, 2025-03-31) — Deferred Tax: -174000.00
GENI cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 16396000.00
GENI cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 16396000.00
GENI income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 248432320.00
GENI income_statement (quarterly, 2025-03-31) — Diluted EPS: -0.03
GENI income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: -8198000.00
GENI cash_flow (quarterly, 2025-03-31) — Dividends Received Cfi: 2498000.00
GENI income_statement (quarterly, 2025-03-31) — EBIT: -19692000.00
GENI income_statement (quarterly, 2025-03-31) — EBITDA: -3296000.00
GENI income_statement (quarterly, 2025-03-31) — Earnings From Equity Interest Net Of Tax: 94000.00
GENI cash_flow (quarterly, 2025-03-31) — Earnings Losses From Equity Investments: -94000.00
GENI cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: 2201000.00
GENI cash_flow (quarterly, 2025-03-31) — End Cash Position: 235662000.00
GENI cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: 143995000.00
GENI cash_flow (quarterly, 2025-03-31) — Free Cash Flow: -48271000.00
GENI income_statement (quarterly, 2025-03-31) — Gain On Sale Of Ppe: -12000.00
GENI income_statement (quarterly, 2025-03-31) — Gain On Sale Of Security: 12249000.00
GENI balance_sheet (quarterly, 2025-03-31) — Gains Losses Not Affecting Retained Earnings: -34834000.00
GENI income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 34535000.00
GENI balance_sheet (quarterly, 2025-03-31) — Goodwill: 326011000.00
GENI balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 441327000.00
GENI balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 167594000.00
GENI balance_sheet (quarterly, 2025-03-31) — Gross PPE: 34603000.00
GENI income_statement (quarterly, 2025-03-31) — Gross Profit: 35202000.00
GENI cash_flow (quarterly, 2025-03-31) — Income Tax Paid Supplemental Data: 919000.00
GENI balance_sheet (quarterly, 2025-03-31) — Income Tax Payable: 1304000.00
GENI income_statement (quarterly, 2025-03-31) — Interest Income: 437000.00
GENI income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 437000.00
GENI cash_flow (quarterly, 2025-03-31) — Interest Paid Supplemental Data: 644000.00
GENI balance_sheet (quarterly, 2025-03-31) — Inventory: 432000.00
GENI balance_sheet (quarterly, 2025-03-31) — Invested Capital: 710858000.00
GENI cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: -14975000.00
GENI balance_sheet (quarterly, 2025-03-31) — Investments And Advances: 29313000.00
GENI cash_flow (quarterly, 2025-03-31) — Issuance Of Capital Stock: 144000000.00
GENI balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 11444000.00
GENI balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 11444000.00
GENI cash_flow (quarterly, 2025-03-31) — Long Term Debt Payments: -5000.00
GENI cash_flow (quarterly, 2025-03-31) — Net Common Stock Issuance: 144000000.00
GENI cash_flow (quarterly, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: -12382000.00
GENI income_statement (quarterly, 2025-03-31) — Net Income: -8198000.00
GENI income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: -8198000.00
GENI income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: -8198000.00
GENI income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: -8198000.00
GENI income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: -8198000.00
GENI cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: -8198000.00
GENI income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: -8198000.00
GENI cash_flow (quarterly, 2025-03-31) — Net Intangibles Purchase And Sale: 0.00
GENI income_statement (quarterly, 2025-03-31) — Net Interest Income: 437000.00
GENI cash_flow (quarterly, 2025-03-31) — Net Issuance Payments Of Debt: -5000.00
GENI cash_flow (quarterly, 2025-03-31) — Net Long Term Debt Issuance: -5000.00
GENI income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: 437000.00
GENI balance_sheet (quarterly, 2025-03-31) — Net PPE: 34603000.00
GENI cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: -4124000.00
GENI cash_flow (quarterly, 2025-03-31) — Net Short Term Debt Issuance: 0.00
GENI balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 269516000.00
GENI balance_sheet (quarterly, 2025-03-31) — Non Current Accounts Receivable: 624000.00
GENI balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Assets: 2581000.00
GENI balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Liabilities: 13680000.00
GENI balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 1244000.00
GENI balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 13680000.00
GENI balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 1646000.00
GENI income_statement (quarterly, 2025-03-31) — Normalized EBITDA: -14801000.00
GENI income_statement (quarterly, 2025-03-31) — Normalized Income: -17286950.00
GENI cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: -30798000.00
GENI cash_flow (quarterly, 2025-03-31) — Operating Gains Losses: -12464000.00
GENI income_statement (quarterly, 2025-03-31) — Operating Income: -19692000.00
GENI income_statement (quarterly, 2025-03-31) — Operating Revenue: 143991000.00
GENI balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 236876079.00
GENI balance_sheet (quarterly, 2025-03-31) — Other Current Borrowings: 15000.00
GENI balance_sheet (quarterly, 2025-03-31) — Other Equity Adjustments: -34834000.00
GENI income_statement (quarterly, 2025-03-31) — Other Gand A: 34535000.00
GENI income_statement (quarterly, 2025-03-31) — Other Income Expense: 11505000.00
GENI balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 115316000.00
GENI cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: 1201000.00
GENI balance_sheet (quarterly, 2025-03-31) — Other Payable: 705000.00
GENI balance_sheet (quarterly, 2025-03-31) — Other Properties: 34603000.00
GENI balance_sheet (quarterly, 2025-03-31) — Other Receivables: 32034000.00
GENI balance_sheet (quarterly, 2025-03-31) — Payables: 42724000.00
GENI balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 109535000.00
GENI balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 37331000.00
GENI income_statement (quarterly, 2025-03-31) — Pretax Income: -7750000.00
GENI cash_flow (quarterly, 2025-03-31) — Provisionand Write Offof Assets: 95000.00
GENI cash_flow (quarterly, 2025-03-31) — Purchase Of Intangibles: 0.00
GENI cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: -4124000.00
GENI balance_sheet (quarterly, 2025-03-31) — Receivables: 121953000.00
GENI income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 108789000.00
GENI income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 16396000.00
GENI cash_flow (quarterly, 2025-03-31) — Repayment Of Debt: -5000.00
GENI income_statement (quarterly, 2025-03-31) — Research And Development: 8946000.00
GENI balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 25839000.00
GENI income_statement (quarterly, 2025-03-31) — Restructuring And Mergern Acquisition: 732000.00
GENI balance_sheet (quarterly, 2025-03-31) — Retained Earnings: -1095725000.00
GENI income_statement (quarterly, 2025-03-31) — Selling And Marketing Expense: 11413000.00
GENI income_statement (quarterly, 2025-03-31) — Selling General And Administration: 45948000.00
GENI balance_sheet (quarterly, 2025-03-31) — Share Issued: 240982027.00
GENI cash_flow (quarterly, 2025-03-31) — Short Term Debt Payments: 0.00
GENI income_statement (quarterly, 2025-03-31) — Special Income Charges: -744000.00
GENI cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 12835000.00
GENI balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 710843000.00
GENI balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 269516000.00
GENI income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 2416050.00
GENI income_statement (quarterly, 2025-03-31) — Tax Provision: 542000.00
GENI income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.21
GENI balance_sheet (quarterly, 2025-03-31) — Taxes Receivable: 8325000.00
GENI balance_sheet (quarterly, 2025-03-31) — Total Assets: 906688000.00
GENI balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 710843000.00
GENI balance_sheet (quarterly, 2025-03-31) — Total Debt: 14423000.00
GENI balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 710843000.00
GENI income_statement (quarterly, 2025-03-31) — Total Expenses: 163683000.00
GENI balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 195845000.00
GENI balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 510094000.00
GENI balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 25124000.00
GENI income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: -20424000.00
GENI balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 2057000.00
GENI income_statement (quarterly, 2025-03-31) — Total Unusual Items: 11505000.00
GENI income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 11505000.00
GENI balance_sheet (quarterly, 2025-03-31) — Treasury Shares Number: 4105948.00
GENI balance_sheet (quarterly, 2025-03-31) — Treasury Stock: 17653000.00
GENI balance_sheet (quarterly, 2025-03-31) — Working Capital: 225873000.00
GENI income_statement (quarterly, 2025-03-31) — Write Off: 0.00
GENI income_statement (quarterly, 2025-06-30) — +Operating Expense: 87525000.00
GENI income_statement (quarterly, 2025-06-30) — +Total Revenue: 118719000.00
GENI balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 30120000.00
GENI balance_sheet (quarterly, 2025-06-30) — Accounts Receivable: 83750000.00
GENI balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 1941470000.00
GENI balance_sheet (quarterly, 2025-06-30) — Allowance For Doubtful Accounts Receivable: -4500000.00
GENI income_statement (quarterly, 2025-06-30) — Basic Average Shares: 253220241.00
GENI income_statement (quarterly, 2025-06-30) — Basic EPS: -0.21
GENI cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 235662000.00
GENI cash_flow (quarterly, 2025-06-30) — Capital Expenditure: -20187000.00
GENI cash_flow (quarterly, 2025-06-30) — Capital Expenditure Reported: -15465000.00
GENI balance_sheet (quarterly, 2025-06-30) — Capital Lease Obligations: 30564000.00
GENI balance_sheet (quarterly, 2025-06-30) — Capital Stock: 2426000.00
GENI balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 221561000.00
GENI balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 221561000.00
GENI cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: -6000.00
GENI cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: -19889000.00
GENI cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: 1035000.00
GENI cash_flow (quarterly, 2025-06-30) — Change In Account Payable: -9843000.00
GENI cash_flow (quarterly, 2025-06-30) — Change In Accrued Expense: -2657000.00
GENI cash_flow (quarterly, 2025-06-30) — Change In Other Current Assets: -1553000.00
GENI cash_flow (quarterly, 2025-06-30) — Change In Other Current Liabilities: 5175000.00
GENI cash_flow (quarterly, 2025-06-30) — Change In Other Working Capital: 2446000.00
GENI cash_flow (quarterly, 2025-06-30) — Change In Payable: -9843000.00
GENI cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: -12500000.00
GENI cash_flow (quarterly, 2025-06-30) — Change In Prepaid Assets: -113000.00
GENI cash_flow (quarterly, 2025-06-30) — Change In Receivables: -12056000.00
GENI cash_flow (quarterly, 2025-06-30) — Change In Working Capital: -18601000.00
GENI cash_flow (quarterly, 2025-06-30) — Changes In Account Receivables: -2233000.00
GENI cash_flow (quarterly, 2025-06-30) — Changes In Cash: -18860000.00
GENI balance_sheet (quarterly, 2025-06-30) — Common Stock: 2426000.00
GENI balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 720147000.00
GENI cash_flow (quarterly, 2025-06-30) — Common Stock Issuance: 0.00
GENI income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 109832000.00
GENI balance_sheet (quarterly, 2025-06-30) — Current Accrued Expenses: 64154000.00
GENI balance_sheet (quarterly, 2025-06-30) — Current Assets: 395730000.00
GENI balance_sheet (quarterly, 2025-06-30) — Current Capital Lease Obligation: 3757000.00
GENI balance_sheet (quarterly, 2025-06-30) — Current Debt: 10000.00
GENI balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 3767000.00
GENI balance_sheet (quarterly, 2025-06-30) — Current Deferred Assets: 1169000.00
GENI balance_sheet (quarterly, 2025-06-30) — Current Deferred Liabilities: 60658000.00
GENI balance_sheet (quarterly, 2025-06-30) — Current Deferred Revenue: 60641000.00
GENI balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 167628000.00
GENI balance_sheet (quarterly, 2025-06-30) — Current Provisions: 4800000.00
GENI cash_flow (quarterly, 2025-06-30) — Deferred Income Tax: -693000.00
GENI cash_flow (quarterly, 2025-06-30) — Deferred Tax: -693000.00
GENI cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 15278000.00
GENI cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 15278000.00
GENI income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 253220241.00
GENI income_statement (quarterly, 2025-06-30) — Diluted EPS: -0.21
GENI income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: -53948000.00
GENI cash_flow (quarterly, 2025-06-30) — Dividends Received Cfi: 289000.00
GENI income_statement (quarterly, 2025-06-30) — EBIT: -78638000.00
GENI income_statement (quarterly, 2025-06-30) — EBITDA: -63360000.00
GENI income_statement (quarterly, 2025-06-30) — Earnings From Equity Interest Net Of Tax: 944000.00
GENI cash_flow (quarterly, 2025-06-30) — Earnings Losses From Equity Investments: -944000.00
GENI cash_flow (quarterly, 2025-06-30) — Effect Of Exchange Rate Changes: 4759000.00
GENI cash_flow (quarterly, 2025-06-30) — End Cash Position: 221561000.00
GENI cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: -6000.00
GENI cash_flow (quarterly, 2025-06-30) — Free Cash Flow: -19152000.00
GENI income_statement (quarterly, 2025-06-30) — Gain On Sale Of Ppe: -1000.00
GENI income_statement (quarterly, 2025-06-30) — Gain On Sale Of Security: 26992000.00
GENI balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: -56423000.00
GENI income_statement (quarterly, 2025-06-30) — General And Administrative Expense: 64500000.00
GENI balance_sheet (quarterly, 2025-06-30) — Goodwill: 326011000.00
GENI balance_sheet (quarterly, 2025-06-30) — Goodwill And Other Intangible Assets: 442342000.00
GENI balance_sheet (quarterly, 2025-06-30) — Gross Accounts Receivable: 88250000.00
GENI balance_sheet (quarterly, 2025-06-30) — Gross PPE: 54699000.00
GENI income_statement (quarterly, 2025-06-30) — Gross Profit: 8887000.00
GENI cash_flow (quarterly, 2025-06-30) — Income Tax Paid Supplemental Data: 765000.00
GENI balance_sheet (quarterly, 2025-06-30) — Income Tax Payable: 2464000.00
GENI cash_flow (quarterly, 2025-06-30) — Interest Paid Supplemental Data: 986000.00
GENI balance_sheet (quarterly, 2025-06-30) — Inventory: 408000.00
GENI balance_sheet (quarterly, 2025-06-30) — Invested Capital: 720157000.00
GENI cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: -19889000.00
GENI balance_sheet (quarterly, 2025-06-30) — Investments And Advances: 29974000.00
GENI cash_flow (quarterly, 2025-06-30) — Issuance Of Capital Stock: 0.00
GENI balance_sheet (quarterly, 2025-06-30) — Long Term Capital Lease Obligation: 26807000.00
GENI balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 26807000.00
GENI cash_flow (quarterly, 2025-06-30) — Net Common Stock Issuance: 0.00
GENI cash_flow (quarterly, 2025-06-30) — Net Foreign Currency Exchange Gain Loss: -26594000.00
GENI income_statement (quarterly, 2025-06-30) — Net Income: -53948000.00
GENI income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: -53948000.00
GENI income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: -53948000.00
GENI income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: -53948000.00
GENI income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: -53948000.00
GENI cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: -53948000.00
GENI income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: -53948000.00
GENI cash_flow (quarterly, 2025-06-30) — Net Intangibles Purchase And Sale: -449000.00
GENI income_statement (quarterly, 2025-06-30) — Net Interest Income: 556000.00
GENI cash_flow (quarterly, 2025-06-30) — Net Issuance Payments Of Debt: -6000.00
GENI income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: 556000.00
GENI balance_sheet (quarterly, 2025-06-30) — Net PPE: 54699000.00
GENI cash_flow (quarterly, 2025-06-30) — Net PPE Purchase And Sale: -4273000.00
GENI cash_flow (quarterly, 2025-06-30) — Net Short Term Debt Issuance: -11000.00
GENI balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 277805000.00
GENI balance_sheet (quarterly, 2025-06-30) — Non Current Accounts Receivable: 750000.00
GENI balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Assets: 2567000.00
GENI balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Liabilities: 13196000.00
GENI balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Assets: 1453000.00
GENI balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Liabilities: 13196000.00
GENI balance_sheet (quarterly, 2025-06-30) — Non Current Prepaid Assets: 1716000.00
GENI income_statement (quarterly, 2025-06-30) — Normalized EBITDA: -88298000.00
GENI income_statement (quarterly, 2025-06-30) — Normalized Income: -73649020.00
GENI cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: 1035000.00
GENI cash_flow (quarterly, 2025-06-30) — Operating Gains Losses: -27537000.00
GENI income_statement (quarterly, 2025-06-30) — Operating Income: -78638000.00
GENI income_statement (quarterly, 2025-06-30) — Operating Revenue: 118719000.00
GENI balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 238441220.00
GENI balance_sheet (quarterly, 2025-06-30) — Other Current Borrowings: 10000.00
GENI balance_sheet (quarterly, 2025-06-30) — Other Equity Adjustments: -56423000.00
GENI income_statement (quarterly, 2025-06-30) — Other Gand A: 64500000.00
GENI income_statement (quarterly, 2025-06-30) — Other Income Expense: 24938000.00
GENI balance_sheet (quarterly, 2025-06-30) — Other Intangible Assets: 116331000.00
GENI cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: 1617000.00
GENI balance_sheet (quarterly, 2025-06-30) — Other Payable: 873000.00
GENI balance_sheet (quarterly, 2025-06-30) — Other Properties: 54699000.00
GENI balance_sheet (quarterly, 2025-06-30) — Other Receivables: 41968000.00
GENI balance_sheet (quarterly, 2025-06-30) — Payables: 34249000.00
GENI balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 98403000.00
GENI balance_sheet (quarterly, 2025-06-30) — Prepaid Assets: 37322000.00
GENI income_statement (quarterly, 2025-06-30) — Pretax Income: -53144000.00
GENI cash_flow (quarterly, 2025-06-30) — Provisionand Write Offof Assets: 78000.00
GENI cash_flow (quarterly, 2025-06-30) — Purchase Of Intangibles: -449000.00
GENI cash_flow (quarterly, 2025-06-30) — Purchase Of PPE: -4273000.00
GENI balance_sheet (quarterly, 2025-06-30) — Receivables: 135270000.00
GENI income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 109832000.00
GENI income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 15278000.00
GENI cash_flow (quarterly, 2025-06-30) — Repayment Of Debt: -6000.00
GENI income_statement (quarterly, 2025-06-30) — Research And Development: 8726000.00
GENI balance_sheet (quarterly, 2025-06-30) — Restricted Cash: 0.00
GENI income_statement (quarterly, 2025-06-30) — Restructuring And Mergern Acquisition: 2053000.00
GENI balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -1149673000.00
GENI income_statement (quarterly, 2025-06-30) — Selling And Marketing Expense: 14299000.00
GENI income_statement (quarterly, 2025-06-30) — Selling General And Administration: 78799000.00
GENI balance_sheet (quarterly, 2025-06-30) — Share Issued: 242547168.00
GENI cash_flow (quarterly, 2025-06-30) — Short Term Debt Payments: -11000.00
GENI income_statement (quarterly, 2025-06-30) — Special Income Charges: -2054000.00
GENI cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 84841000.00
GENI balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 720147000.00
GENI balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 277805000.00
GENI income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 5236980.00
GENI income_statement (quarterly, 2025-06-30) — Tax Provision: 1748000.00
GENI income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.21
GENI balance_sheet (quarterly, 2025-06-30) — Taxes Receivable: 9552000.00
GENI balance_sheet (quarterly, 2025-06-30) — Total Assets: 927778000.00
GENI balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 720147000.00
GENI balance_sheet (quarterly, 2025-06-30) — Total Debt: 30574000.00
GENI balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 720147000.00
GENI income_statement (quarterly, 2025-06-30) — Total Expenses: 197357000.00
GENI balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 207631000.00
GENI balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 532048000.00
GENI balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 40003000.00
GENI income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: -80691000.00
GENI income_statement (quarterly, 2025-06-30) — Total Other Finance Cost: -556000.00
GENI balance_sheet (quarterly, 2025-06-30) — Total Tax Payable: 3256000.00
GENI income_statement (quarterly, 2025-06-30) — Total Unusual Items: 24938000.00
GENI income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 24938000.00
GENI balance_sheet (quarterly, 2025-06-30) — Treasury Shares Number: 4105948.00
GENI balance_sheet (quarterly, 2025-06-30) — Treasury Stock: 17653000.00
GENI balance_sheet (quarterly, 2025-06-30) — Working Capital: 228102000.00
GENI income_statement (quarterly, 2025-09-30) — +Operating Expense: 64258000.00
GENI income_statement (quarterly, 2025-09-30) — +Total Revenue: 166283000.00
GENI balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 59921000.00
GENI balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 132385000.00
GENI balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 1966811000.00
GENI balance_sheet (quarterly, 2025-09-30) — Allowance For Doubtful Accounts Receivable: -3860000.00
GENI income_statement (quarterly, 2025-09-30) — Basic Average Shares: 257661292.00
GENI income_statement (quarterly, 2025-09-30) — Basic EPS: -0.11
GENI cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 221561000.00
GENI cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -23918000.00
GENI cash_flow (quarterly, 2025-09-30) — Capital Expenditure Reported: -15852000.00
GENI balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 30172000.00
GENI balance_sheet (quarterly, 2025-09-30) — Capital Stock: 2429000.00
GENI balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 207792000.00
GENI balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 207792000.00
GENI cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: -6000.00
GENI cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: -38728000.00
GENI cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: 27204000.00
GENI cash_flow (quarterly, 2025-09-30) — Change In Account Payable: 29800000.00
GENI cash_flow (quarterly, 2025-09-30) — Change In Accrued Expense: 15942000.00
GENI cash_flow (quarterly, 2025-09-30) — Change In Other Current Assets: -4827000.00
GENI cash_flow (quarterly, 2025-09-30) — Change In Other Current Liabilities: 2351000.00
GENI cash_flow (quarterly, 2025-09-30) — Change In Other Working Capital: 33739000.00
GENI cash_flow (quarterly, 2025-09-30) — Change In Payable: 29800000.00
GENI cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: 45742000.00
GENI cash_flow (quarterly, 2025-09-30) — Change In Prepaid Assets: -11235000.00
GENI cash_flow (quarterly, 2025-09-30) — Change In Receivables: -59944000.00
GENI cash_flow (quarterly, 2025-09-30) — Change In Working Capital: 5826000.00
GENI cash_flow (quarterly, 2025-09-30) — Changes In Account Receivables: -47698000.00
GENI cash_flow (quarterly, 2025-09-30) — Changes In Cash: -11530000.00
GENI balance_sheet (quarterly, 2025-09-30) — Common Stock: 2429000.00
GENI balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 722530000.00
GENI cash_flow (quarterly, 2025-09-30) — Common Stock Issuance: 0.00
GENI income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 124963000.00
GENI balance_sheet (quarterly, 2025-09-30) — Current Accrued Expenses: 87595000.00
GENI balance_sheet (quarterly, 2025-09-30) — Current Assets: 466401000.00
GENI balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 4076000.00
GENI balance_sheet (quarterly, 2025-09-30) — Current Debt: 4000.00
GENI balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 4080000.00
GENI balance_sheet (quarterly, 2025-09-30) — Current Deferred Assets: 1164000.00
GENI balance_sheet (quarterly, 2025-09-30) — Current Deferred Liabilities: 98779000.00
GENI balance_sheet (quarterly, 2025-09-30) — Current Deferred Revenue: 98779000.00
GENI balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 269295000.00
GENI balance_sheet (quarterly, 2025-09-30) — Current Provisions: 4800000.00
GENI cash_flow (quarterly, 2025-09-30) — Deferred Income Tax: -1495000.00
GENI cash_flow (quarterly, 2025-09-30) — Deferred Tax: -1495000.00
GENI cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 18761000.00
GENI cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 18761000.00
GENI income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 257661292.00
GENI income_statement (quarterly, 2025-09-30) — Diluted EPS: -0.11
GENI income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: -28814000.00
GENI cash_flow (quarterly, 2025-09-30) — Dividends Received Cfi: 0.00
GENI income_statement (quarterly, 2025-09-30) — EBIT: -22938000.00
GENI income_statement (quarterly, 2025-09-30) — EBITDA: -4177000.00
GENI income_statement (quarterly, 2025-09-30) — Earnings From Equity Interest Net Of Tax: 1817000.00
GENI cash_flow (quarterly, 2025-09-30) — Earnings Losses From Equity Investments: -1817000.00
GENI cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: -2239000.00
GENI cash_flow (quarterly, 2025-09-30) — End Cash Position: 207792000.00
GENI cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: -6000.00
GENI cash_flow (quarterly, 2025-09-30) — Free Cash Flow: 3286000.00
GENI income_statement (quarterly, 2025-09-30) — Gain On Sale Of Ppe: 39000.00
GENI income_statement (quarterly, 2025-09-30) — Gain On Sale Of Security: -7519000.00
GENI balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: -50570000.00
GENI income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 45670000.00
GENI balance_sheet (quarterly, 2025-09-30) — Goodwill: 338750000.00
GENI balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 487662000.00
GENI balance_sheet (quarterly, 2025-09-30) — Gross Accounts Receivable: 136245000.00
GENI balance_sheet (quarterly, 2025-09-30) — Gross PPE: 58193000.00
GENI income_statement (quarterly, 2025-09-30) — Gross Profit: 41320000.00
GENI cash_flow (quarterly, 2025-09-30) — Income Tax Paid Supplemental Data: 1319000.00
GENI balance_sheet (quarterly, 2025-09-30) — Income Tax Payable: 793000.00
GENI cash_flow (quarterly, 2025-09-30) — Interest Paid Supplemental Data: 994000.00
GENI balance_sheet (quarterly, 2025-09-30) — Inventory: 374000.00
GENI balance_sheet (quarterly, 2025-09-30) — Invested Capital: 722534000.00
GENI cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: -38728000.00
GENI balance_sheet (quarterly, 2025-09-30) — Investments And Advances: 31779000.00
GENI cash_flow (quarterly, 2025-09-30) — Issuance Of Capital Stock: 0.00
GENI balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 26096000.00
GENI balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 26096000.00
GENI cash_flow (quarterly, 2025-09-30) — Net Common Stock Issuance: 0.00
GENI cash_flow (quarterly, 2025-09-30) — Net Foreign Currency Exchange Gain Loss: 7833000.00
GENI income_statement (quarterly, 2025-09-30) — Net Income: -28814000.00
GENI income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: -28814000.00
GENI income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: -28814000.00
GENI income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -28814000.00
GENI income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -28814000.00
GENI cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: -28814000.00
GENI income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: -28814000.00
GENI cash_flow (quarterly, 2025-09-30) — Net Intangibles Purchase And Sale: -810000.00
GENI income_statement (quarterly, 2025-09-30) — Net Interest Income: -138000.00
GENI cash_flow (quarterly, 2025-09-30) — Net Issuance Payments Of Debt: -6000.00
GENI income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -138000.00
GENI cash_flow (quarterly, 2025-09-30) — Net Other Investing Changes: 31000.00
GENI balance_sheet (quarterly, 2025-09-30) — Net PPE: 58193000.00
GENI cash_flow (quarterly, 2025-09-30) — Net PPE Purchase And Sale: -7256000.00
GENI balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 234868000.00
GENI balance_sheet (quarterly, 2025-09-30) — Non Current Accounts Receivable: 823000.00
GENI balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Assets: 2650000.00
GENI balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Liabilities: 12184000.00
GENI balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Assets: 1546000.00
GENI balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 11795000.00
GENI balance_sheet (quarterly, 2025-09-30) — Non Current Prepaid Assets: 1592000.00
GENI income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 5970000.00
GENI income_statement (quarterly, 2025-09-30) — Normalized Income: -19458651.09
GENI cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: 27204000.00
GENI cash_flow (quarterly, 2025-09-30) — Operating Gains Losses: 5977000.00
GENI income_statement (quarterly, 2025-09-30) — Operating Income: -22938000.00
GENI income_statement (quarterly, 2025-09-30) — Operating Revenue: 166283000.00
GENI balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 238718120.00
GENI balance_sheet (quarterly, 2025-09-30) — Other Current Borrowings: 4000.00
GENI balance_sheet (quarterly, 2025-09-30) — Other Equity Adjustments: -50570000.00
GENI income_statement (quarterly, 2025-09-30) — Other Gand A: 45670000.00
GENI income_statement (quarterly, 2025-09-30) — Other Income Expense: -10147000.00
GENI balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 148912000.00
GENI cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: 1503000.00
GENI balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 3611000.00
GENI balance_sheet (quarterly, 2025-09-30) — Other Payable: 12514000.00
GENI balance_sheet (quarterly, 2025-09-30) — Other Properties: 58193000.00
GENI balance_sheet (quarterly, 2025-09-30) — Other Receivables: 54573000.00
GENI balance_sheet (quarterly, 2025-09-30) — Payables: 74041000.00
GENI balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 161636000.00
GENI balance_sheet (quarterly, 2025-09-30) — Prepaid Assets: 56337000.00
GENI income_statement (quarterly, 2025-09-30) — Pretax Income: -33223000.00
GENI cash_flow (quarterly, 2025-09-30) — Provisionand Write Offof Assets: 102000.00
GENI cash_flow (quarterly, 2025-09-30) — Purchase Of Intangibles: -810000.00
GENI cash_flow (quarterly, 2025-09-30) — Purchase Of PPE: -7256000.00
GENI balance_sheet (quarterly, 2025-09-30) — Receivables: 200734000.00
GENI income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 124963000.00
GENI income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 18761000.00
GENI cash_flow (quarterly, 2025-09-30) — Repayment Of Debt: -6000.00
GENI income_statement (quarterly, 2025-09-30) — Research And Development: 4943000.00
GENI balance_sheet (quarterly, 2025-09-30) — Restricted Cash: 0.00
GENI income_statement (quarterly, 2025-09-30) — Restructuring And Mergern Acquisition: 2667000.00
GENI balance_sheet (quarterly, 2025-09-30) — Retained Earnings: -1178487000.00
GENI income_statement (quarterly, 2025-09-30) — Selling And Marketing Expense: 13645000.00
GENI income_statement (quarterly, 2025-09-30) — Selling General And Administration: 59315000.00
GENI balance_sheet (quarterly, 2025-09-30) — Share Issued: 242824068.00
GENI income_statement (quarterly, 2025-09-30) — Special Income Charges: -2628000.00
GENI cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 25344000.00
GENI balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 722530000.00
GENI balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 234868000.00
GENI income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: -791651.09
GENI income_statement (quarterly, 2025-09-30) — Tax Provision: -2592000.00
GENI income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.08
GENI balance_sheet (quarterly, 2025-09-30) — Taxes Receivable: 13776000.00
GENI balance_sheet (quarterly, 2025-09-30) — Total Assets: 1049100000.00
GENI balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 722530000.00